(MedPage Today) — Adding a dual GLP-1/GIP receptor agonist to the psoriasis drug ixekizumab (Taltz) significantly improved outcomes in adults with difficult-to-treat plaque psoriasis due to overweight or obesity, the open-label TOGETHER-PsO trial…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
